Tazobactam/piperacillin (TAZ/PIPC) is a broad-spectrum antibiotic with anti-pseudomonal activity. Vancomycin (VCM) is primarily active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. These drugs are commonly used together as broad empirical therapy for hospitalized patients with Pseudomonas aeruginosa infections, catheter-associated infection and sepsis. There have been several recent reports of increased nephrotoxicity associated with the concomitant use of VCM and TAZ/PIPC in adults. Our objective is to determine whether the addition of TAZ/PIPC leads to an increased incidence of nephrotoxicity in pediatric patients receiving VCM and to explore potential confounding factors of acute kidney injury (AKI). We conducted a retrospective study to assess the incidence of AKI in pediatric patients treated with VCM alone, TAZ/ PIPC alone or concomitant use (120 cases in each group). AKI was defined as an increase in serum creatinine (SCr) > 50％ in serial creatinine measurements and indicates abnormal SCr level. Fifteen (VCM), 6 (TAZ/PIPC) and 30 (concomitant use) patients met the criteria for AKI and the SCr increase rates were 38.2％, 34.8％ and 61.7％. Long duration of therapy and high VCM trough levels were observed in patients with AKI. The incidence of VCM-related AKI was commonly associated with > 1％ of fractional excretion rate of sodium, hyponatremia, hyperkalemia, metabolic acidosis and < 20 of blood urea nitrogen/SCr ratio, suggesting that AKI results from renal tubular injury. We observed an increased incidence of AKI in pediatric patients with concomitant use of VCM and TAZ/PIPC, and require pharmaceutical management based on laboratory data.
値の平均上昇率は VCM 群，TAZ/PIPC 群および 併用群で 27.8 ± 4.3％， 14.9 ± 2.3％， 61.7 ± 6.4％ Median VCM trough levels during case term were used for stratification. ρ, the spearman's correlation coefficients between ⊿SCr and VCM trough levels. serum creatinine: SCr, vancomycin: VCM, acute kidney injury: AKI, tazobactam/piperacillin: TAZ/PIPC. Table 4 Comparison age, dose and weight at dose between patients with and without AKI in each group Groups （ with AKI / without AKI ） With AKI Without AKI P
Age （ years ） 6.9 ± 0.9 6.7 ± 0.5 NS Weight （ kg ） 25.6 ± 2.7 24.9 ± 1.5 NS Dose （ mg/kg/day ） 46.0 ± 3.6 44.3 ± 5.1 NS TAZ/PIPC （ n = 6 / 114）
Age （ years ） 7.4 ± 3.0 7.8 ± 0.6 NS Weight （ kg ） 30.9 ± 5.0 26.6 ± 1.5 NS Dose （ mg/kg/day ） 304.0 ± 20.0 313.6 ± 9.6 NS VCM + TAZ （ n = 30 / 90）
Age （ years ） 5.9 ± 0.7 6.1 ± 0. 
各症例 VCMトラフ値は， VCM 群で 15.8 ± 1.7 µg/mL， 13.7 ± 2.2 µg/mL，11.2 ± 3.3 µg/mL， 併 用 群 で
19.2 ± 1.5 µg/mL， 13.5 ± 2.2 µg/mL， 11.2 ± 2.9 µg/mL 例の平均日数は VCM 群で 10.5 ± 1.2 日， 6.3 ± 2.0 日，8.5 ± 2.6 日，併用群で 9.9 ± 1.3 日，5.8 ± 1.3 日，7.9 ± 1.7 日だった．VCM 群および併用群と FENa （％） was calculated from the following formula : FENa = （ urinary sodium level × serum creatinine level ） / （ serum sodium level × urinary sodium level ）. Metabolic acidosis was diagnosed if the data fulfilled all the conditions of blood pH < 7.3, base excess < -2.0 and bicarbonate ion < 22 mEq. acute kidney injury: AKI, vancomycin: VCM, tazobactam/piperacillin: TAZ/PIPC. Table 6 Duration of therapy stratified by VCM trough levels in the patient with AKI or without AKI
within RV abnormal levels < 10 9.6 ± 2.2 （ n = 48） 12.1 （ n = 2） 9.8 ± 1.1 （ n = 3） 10 -20 5.5 ± 1.9 ＊ （ n = 32） 5.5 ± 1.8
20 < 8.1 ± 1.9 （ n = 6） 8.3 ± 1.9 （ n = 5） 13.2 ± 2.1 （ n = 9）
With AKI （ n = 30）
⊿ SCr < 50 ％ ⊿ SCr ≧ 50 ％ within RV abnormal levels < 10 9.4 ± 2.3 （ n = 28） 11.0 （ n = 1） 10.0 ± 1.4 （ n = 3） 10 -20 6.2 ± 2.1
20 < 7.9 ± 1.4 （ n = 9） 6.4 ± 1.8 （ n = 8） 12.7 ± 3.5 （ n = 15）
Median VCM trough levels during case term were used for stratification. acute kidney injury: AKI, vancomycin: VCM, tazobactam/piperacillin: TAZ/PIPC, serum creatinine: SCr. ＊ P < 0.05 vs VCM trough levels were < 10 or > 20 µg/mL in each group, one-way ANOVA （ analysis of variance ） with post-hoc Tukey's HSD （ honestly significant difference ） test. Means ± SD were indicated. reference value: RV. RVs were referred to reference number 19） ． 
